arrow
M

Mazyar Shadman

university of washington
H指数:46
被引数:8,618

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia

绝对淋巴细胞计数单一进展在慢性淋巴细胞白血病中的发生率和临床影响

2026-09-010
PRE
Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma

滤泡性淋巴瘤中,嵌合抗原受体T细胞疗法后双特异性抗体疗法的真实世界结局

2026-06-180
OAAI
Five-year survival outcomes of lisocabtagene maraleucel in R/R LBCL from the TRANSCEND NHL 001 study

lisocabtagene maraleucel在TRANSCEND NHL 001研究中复发/难治性LBCL的五年生存结局

Blood
IF23.1
2026-06-050
OAAI
Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome

早期神经系统反应预测anakinra治疗免疫效应细胞相关神经毒性综合征的结局

2026-06-020
OAAI
Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression

奥布替尼在复发/难治性慢性淋巴细胞白血病中的延长无进展生存期:与其他BTK抑制剂的多水平网络Meta回归间接治疗比较

2026-05-230
OAAI
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma

利萨库肽马瑞卢赛尔在复发或难治性大B细胞淋巴瘤患者中的真实世界结局

Blood
IF23.1
2026-03-050
OA
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial

Epcoritamab单药治疗Richter转化(EPCORE CLL-1):一项单臂、多中心、开放标签的Ⅰb/Ⅱ期试验结果

2025-12-080
PRE
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma

髓外疾病与多发性骨髓瘤中B细胞成熟抗原CAR T细胞疗法后的严重毒性与相关。

2025-12-015
OA
Total Body Irradiation Versus Chemotherapy-Only Conditioning in Autologous Hematopoietic Stem Cell Transplantation for relapsed/refractory Large B-Cell Lymphoma

自体造血干细胞移植治疗复发/难治性大B细胞淋巴瘤中全身照射与单纯化疗预处理方案的比较

2025-10-140
PRE